Preeclampsia
Conditions
Brief summary
In this study, the investigators assessed one of the released protein factors during the pathophysiology of preeclampsia. They evaluated vascular endothelial growth factor gene mutation which affects the angiogenesis in case of inadequate placentation and its association with Doppler changes in the pulsatility index of the umbilical artery.
Detailed description
Preeclampsia is a syndrome characterized by occurrence of hypertension and proteinuria after 20 weeks of gestation. The pathophysiology of preeclampsia involves abnormalities in the development of placental vasculature early in pregnancy may result in relative placental under perfusion/hypoxia/ischemia, which then leads to release of factors into the maternal circulation that alter maternal endothelial function and cause hypertension and other manifestations of disease .Vascular endothelial growth factor (VEGF) is a signal protein produced by cells that stimulates vasculogenesis and angiogenesis. It is part of the system that restores the oxygen supply to tissues when blood circulation is inadequate. Human VEGF gene is located on chromosome 6 and consists of 8 exons with alternate splicing, forming a family of proteins. There are several common single nucleotide polymorphisms (SNPs) in the VEGF gene, which could alter gene expression and protein production, and alter the risk of developing diseases characterized by deranged angiogenesis including preeclampsia.
Interventions
DIAGNOSTIC_TESTPCR
Polymerase chain reaction was used to diagnose gene polymorphism.
DEVICEDoppler ultrasound
Doppler ultrasound was used to assess the pulsatility index of the umbilical artery .
Sponsors
Beni-Suef University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
More than 20 weeks gestation. Preeclamptic patients
Exclusion criteria
association with chronic disease (cardiac, hepatic, renal) and if the patient was known to have chronic hypertension. association with auto-immune disease.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Correlation of VEGF gene mutation and preeclampsia | from 20 weeks until delivery | Is VEGF gene polymorphism associated with preeclampsia |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| fetal and neonatal outcomes | from 20 weeks until first postpartum week. | Intrauterine growth restriction |
| maternal outcome | from 20 weeks until delivery | Maternal admission to intensive care unit |
Countries
Egypt
Outcome results
None listed